FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914713665> ?p ?o ?g. }

• W2914713665 endingPage "1336" @default.
• W2914713665 startingPage "1329" @default.
• W2914713665 abstract "Although previous studies compared the efficacy of infliximab (IFX) versus adalimumab (ADA) as the first-line biologics for Crohn's disease (CD), the difference in long-term prognosis based on which biologic was used first has scarcely been reported. In particular, the clinical courses after loss of response (LOR) of the first-line biologics are largely unknown.A multicenter, retrospective study was performed. Disease courses of biologic-naïve CD patients who were started on IFX or ADA treatment were evaluated, even after LOR of the initial biologics.In total, 263 CD patients were eligible for analysis, 183 were treated with IFX first, and 80 were treated with ADA first. The median observation period was 64.2 months. The cumulative steroid-free remission rates and surgery-free rates did not differ significantly between the patients treated with IFX first and those treated with ADA first (log-rank test P = 0.42 and P = 0.74, respectively). In addition, no significant difference was observed in the rate of occurrence of events associated with ineffectiveness (modification of anti-tumor necrosis factor treatment including intensification, switch, discontinuation, or surgery) between the patient groups (log-rank test P = 0.62). The patients treated with IFX first were likely to discontinue the agent due to adverse events, whereas those treated with ADA first were likely to discontinue due to treatment failure or LOR.No significant difference was observed in the long-term prognosis between biologic-naïve patients with CD who were started treatment with IFX first and ADA first." @default.
• W2914713665 created "2019-02-21" @default.
• W2914713665 creator A5001121988 @default.
• W2914713665 creator A5005176846 @default.
• W2914713665 creator A5006080006 @default.
• W2914713665 creator A5008867400 @default.
• W2914713665 creator A5012381067 @default.
• W2914713665 creator A5025318495 @default.
• W2914713665 creator A5028961795 @default.
• W2914713665 creator A5036515552 @default.
• W2914713665 creator A5044539489 @default.
• W2914713665 creator A5052372504 @default.
• W2914713665 creator A5058159958 @default.
• W2914713665 creator A5069038207 @default.
• W2914713665 creator A5072827290 @default.
• W2914713665 creator A5079207200 @default.
• W2914713665 creator A5090599179 @default.
• W2914713665 creator A5091348767 @default.
• W2914713665 date "2019-02-27" @default.
• W2914713665 modified "2023-10-01" @default.
• W2914713665 title "Long‐term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first‐line biologics" @default.
• W2914713665 cites W1547943993 @default.
• W2914713665 cites W1940760407 @default.
• W2914713665 cites W2094778049 @default.
• W2914713665 cites W2096675088 @default.
• W2914713665 cites W2296926020 @default.
• W2914713665 cites W2335895559 @default.
• W2914713665 cites W2404971681 @default.
• W2914713665 cites W2522587402 @default.
• W2914713665 cites W2525802576 @default.
• W2914713665 cites W2566490068 @default.
• W2914713665 cites W2600357914 @default.
• W2914713665 cites W2605392787 @default.
• W2914713665 cites W2611564874 @default.
• W2914713665 cites W2755604283 @default.
• W2914713665 cites W2771677620 @default.
• W2914713665 cites W2773742325 @default.
• W2914713665 doi "https://doi.org/10.1111/jgh.14624" @default.
• W2914713665 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30724387" @default.
• W2914713665 hasPublicationYear "2019" @default.
• W2914713665 type Work @default.
• W2914713665 sameAs 2914713665 @default.
• W2914713665 citedByCount "10" @default.
• W2914713665 countsByYear W29147136652020 @default.
• W2914713665 countsByYear W29147136652021 @default.
• W2914713665 countsByYear W29147136652022 @default.
• W2914713665 crossrefType "journal-article" @default.
• W2914713665 hasAuthorship W2914713665A5001121988 @default.
• W2914713665 hasAuthorship W2914713665A5005176846 @default.
• W2914713665 hasAuthorship W2914713665A5006080006 @default.
• W2914713665 hasAuthorship W2914713665A5008867400 @default.
• W2914713665 hasAuthorship W2914713665A5012381067 @default.
• W2914713665 hasAuthorship W2914713665A5025318495 @default.
• W2914713665 hasAuthorship W2914713665A5028961795 @default.
• W2914713665 hasAuthorship W2914713665A5036515552 @default.
• W2914713665 hasAuthorship W2914713665A5044539489 @default.
• W2914713665 hasAuthorship W2914713665A5052372504 @default.
• W2914713665 hasAuthorship W2914713665A5058159958 @default.
• W2914713665 hasAuthorship W2914713665A5069038207 @default.
• W2914713665 hasAuthorship W2914713665A5072827290 @default.
• W2914713665 hasAuthorship W2914713665A5079207200 @default.
• W2914713665 hasAuthorship W2914713665A5090599179 @default.
• W2914713665 hasAuthorship W2914713665A5091348767 @default.
• W2914713665 hasConcept C10515644 @default.
• W2914713665 hasConcept C126322002 @default.
• W2914713665 hasConcept C141071460 @default.
• W2914713665 hasConcept C167135981 @default.
• W2914713665 hasConcept C197934379 @default.
• W2914713665 hasConcept C2777138892 @default.
• W2914713665 hasConcept C2778715236 @default.
• W2914713665 hasConcept C2779134260 @default.
• W2914713665 hasConcept C2779280984 @default.
• W2914713665 hasConcept C2780132546 @default.
• W2914713665 hasConcept C2993493390 @default.
• W2914713665 hasConcept C66339696 @default.
• W2914713665 hasConcept C71924100 @default.
• W2914713665 hasConcept C90924648 @default.
• W2914713665 hasConceptScore W2914713665C10515644 @default.
• W2914713665 hasConceptScore W2914713665C126322002 @default.
• W2914713665 hasConceptScore W2914713665C141071460 @default.
• W2914713665 hasConceptScore W2914713665C167135981 @default.
• W2914713665 hasConceptScore W2914713665C197934379 @default.
• W2914713665 hasConceptScore W2914713665C2777138892 @default.
• W2914713665 hasConceptScore W2914713665C2778715236 @default.
• W2914713665 hasConceptScore W2914713665C2779134260 @default.
• W2914713665 hasConceptScore W2914713665C2779280984 @default.
• W2914713665 hasConceptScore W2914713665C2780132546 @default.
• W2914713665 hasConceptScore W2914713665C2993493390 @default.
• W2914713665 hasConceptScore W2914713665C66339696 @default.
• W2914713665 hasConceptScore W2914713665C71924100 @default.
• W2914713665 hasConceptScore W2914713665C90924648 @default.
• W2914713665 hasIssue "8" @default.
• W2914713665 hasLocation W29147136651 @default.
• W2914713665 hasLocation W29147136652 @default.
• W2914713665 hasOpenAccess W2914713665 @default.
• W2914713665 hasPrimaryLocation W29147136651 @default.
• W2914713665 hasRelatedWork W1588288904 @default.
• W2914713665 hasRelatedWork W1726928670 @default.

• next